Top Page
Sanofi
(NASDAQ:SNY)
Sanofi (SNY) vs. SPDR S&P 500 ETF (SPY)
Sanofi Business Overview & Revenue Model
Sanofi Earnings Call Summary
Sanofi Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.13B | 44.29B | 41.11B | 40.30B | 39.17B | 37.37B |
| Gross Profit | 30.89B | 31.09B | 28.49B | 28.43B | 26.92B | 25.26B |
| EBITDA | 9.47B | 11.66B | 11.08B | 13.09B | 11.25B | 10.47B |
| Net Income | 9.13B | 5.56B | 5.40B | 8.37B | 6.22B | 12.29B |
Balance Sheet | ||||||
| Total Assets | 124.96B | 132.80B | 126.46B | 126.72B | 120.24B | 114.41B |
| Cash, Cash Equivalents and Short-Term Investments | 15.36B | 7.93B | 8.71B | 12.74B | 10.10B | 13.91B |
| Total Debt | 22.29B | 17.91B | 18.42B | 21.21B | 22.41B | 23.68B |
| Total Liabilities | 54.68B | 54.94B | 52.11B | 51.57B | 51.21B | 51.16B |
| Stockholders Equity | 70.01B | 77.51B | 74.04B | 74.78B | 68.68B | 63.11B |
Cash Flow | ||||||
| Free Cash Flow | 2.09B | 5.89B | 8.64B | 8.32B | 8.48B | 5.33B |
| Operating Cash Flow | 2.09B | 9.08B | 10.26B | 10.53B | 10.52B | 7.45B |
| Investing Cash Flow | -776.00M | -4.41B | -6.20B | -2.08B | -7.30B | 3.59B |
| Financing Cash Flow | -592.00M | -5.76B | -8.05B | -5.82B | -7.06B | -6.49B |
Sanofi Technical Analysis
Sanofi Risk Analysis
Sanofi Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $150.06B | 24.06 | 33.26% | 2.61% | 3.69% | 501.26% | |
| ― | $249.53B | 18.75 | 32.82% | 3.09% | 12.38% | -12.67% | |
| ― | $140.77B | 13.17 | 12.16% | 6.90% | 14.72% | ― | |
| ― | $126.22B | 12.84 | 8.39% | 4.30% | -9.32% | 120.62% | |
| ― | $218.53B | 13.49 | 35.44% | 3.68% | 2.00% | 20.01% | |
| ― | $89.21B | 17.69 | 29.31% | 5.72% | 2.57% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Sanofi Corporate Events
On October 8, 2025, Sanofi announced that its investigational therapy AlphaMedixTM (212Pb-DOTAMTATE) met all primary efficacy endpoints in a phase 2 study for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study showed clinically meaningful benefits in both PRRT-naïve and PRRT-exposed patients, with a manageable safety profile. These results highlight the potential of Targeted Alpha Therapy with lead-212 as a new treatment option, reinforcing Sanofi’s commitment to innovative cancer therapies. The findings will be discussed with health authorities and presented at the 2025 European Society for Medical Oncology Congress.
In September 2025, Sanofi announced that its gene therapy SAR446268 received fast track designation from the US FDA for treating non-congenital myotonic dystrophy type 1, a rare genetic disorder with no approved treatments. This designation aims to expedite the development of SAR446268, which uses RNA interference to target the DMPK gene, potentially addressing key symptoms of the disease. Additionally, Sanofi committed an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation, reinforcing its strategic focus on advancing healthcare solutions.
On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents. If approved, Dupixent would be the first targeted medicine for CSU in the EU in over a decade. This advancement could enhance Sanofi’s market position in the EU and provide new treatment options for patients with CSU who have inadequate responses to existing therapies.
In September 2025, Sanofi announced significant advancements in their product offerings. On September 10, 2025, Tzield was approved in China as the first disease-modifying therapy for stage 2 type 1 diabetes, marking a new era in diabetes care by delaying the onset of stage 3 T1D. This approval aligns with Chinese guidelines emphasizing the protection of beta-cell function. Additionally, on September 11, 2025, Sanofi’s SAR402663 received fast track designation in the US for treating neovascular age-related macular degeneration, enhancing their position in the ophthalmology sector. Furthermore, on September 17, 2025, Sanofi reported positive phase 2a study results for brivekimig in treating hidradenitis suppurativa, underscoring their commitment to addressing unmet medical needs.
On September 4, 2025, Sanofi announced positive results from its COAST 1 phase 3 study, revealing that amlitelimab met all primary and key secondary endpoints in treating moderate-to-severe atopic dermatitis. Amlitelimab, a monoclonal antibody targeting OX40-ligand, showed significant efficacy in skin clearance and disease severity, with potential for dosing only four times a year. These findings highlight amlitelimab’s promise as a differentiated treatment option, supporting Sanofi’s ambition to advance in the atopic dermatitis market.
On August 29, 2025, Sanofi announced that the US FDA approved Wayrilz (rilzabrutinib) as the first Bruton’s tyrosine kinase (BTK) inhibitor for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded to previous treatments. This approval, based on the LUNA 3 phase 3 study, highlights Wayrilz’s potential to improve platelet counts and quality of life for over 25,000 US adults with ITP. The approval underscores Sanofi’s expertise in rare and immunological diseases, potentially positioning Wayrilz as a treatment of choice for ITP, enhancing Sanofi’s market presence in the field of rare blood disorders.
On August 14, 2025, Sanofi announced that its investigational drug rilzabrutinib received orphan designation from the European Medicines Agency for treating IgG4-related disease, a rare immune-mediated condition. This designation highlights Sanofi’s commitment to advancing treatments for rare diseases. The drug, which showed positive results in a Phase 2 study, is also under regulatory review in the US, EU, and China for immune thrombocytopenia, with a US FDA decision expected by August 29, 2025.
On August 6, 2025, Sanofi completed its acquisition of Vigil Neuroscience, Inc., enhancing its early-stage neurology pipeline with VG-3927, a novel TREM2 agonist aimed at treating Alzheimer’s disease. This acquisition, valued at approximately $470 million, is not expected to impact Sanofi’s financial guidance for 2025 and marks a strategic move to strengthen its research in neurodegenerative diseases.
In July 2025, Sanofi released its half-year financial statements and management report, highlighting a decrease in total assets from €132,798 million in December 2024 to €124,959 million in June 2025. This financial update may impact Sanofi’s market positioning and stakeholder confidence, as it reflects changes in the company’s asset management and financial health over the first half of the year.
In July 2025, Sanofi reported a strong performance for the second quarter, with a 10.1% increase in sales at constant exchange rates and a solid growth in business earnings per share (EPS). The company’s pharmaceutical launches, particularly ALTUVIIIO, and the COPD launch of Dupixent significantly contributed to this growth. Sanofi also made progress in its pipeline with several regulatory approvals and acquisitions, including Blueprint in rare diseases. The company has revised its 2025 sales guidance to high single-digit growth, reflecting confidence in its strategic direction and continued focus on R&D and innovation.
In July 2025, Sanofi announced two significant developments in its multiple myeloma treatment portfolio. On July 25, 2025, the European Commission approved Sarclisa in combination with VRd for the treatment of transplant-eligible newly diagnosed multiple myeloma patients, based on positive results from the GMMG-HD7 phase 3 study. This approval marks Sarclisa’s availability in the EU across all lines of therapy for multiple myeloma. Additionally, on July 30, 2025, Sanofi’s SAR446523, a GPRC5D monoclonal antibody, received orphan drug designation in the US for multiple myeloma, highlighting the company’s commitment to addressing unmet needs in cancer care.
In July 2025, Sanofi announced that its SAR446597 therapy received fast track designation from the US FDA for treating geographic atrophy due to age-related macular degeneration, highlighting its potential to address unmet medical needs in retinal diseases. Additionally, Sanofi revealed plans to acquire Vicebio, aiming to expand its respiratory vaccines pipeline, which could enhance its market position and offer new growth opportunities.